Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors

Amanda Rosewell Shaw; Caroline E. Porter; Tiffany Yip; Way-Champ Mah; Mary K. McKenna; Matthew Dysthe; Youngrock Jung; Robin Parihar; Malcolm K. Brenner; Masataka Suzuki

doi:10.1038/s42003-021-01914-8

Communications Biology (Mar 2021)

Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors

Amanda Rosewell Shaw,
Caroline E. Porter,
Tiffany Yip,
Way-Champ Mah,
Mary K. McKenna,
Matthew Dysthe,
Youngrock Jung,
Robin Parihar,
Malcolm K. Brenner,
Masataka Suzuki

Affiliations

Amanda Rosewell Shaw: Department of Medicine, Section of Hematology/Oncology, Baylor College of Medicine
Caroline E. Porter: Department of Medicine, Section of Hematology/Oncology, Baylor College of Medicine
Tiffany Yip: Department of Medicine, Section of Hematology/Oncology, Baylor College of Medicine
Way-Champ Mah: Department of Medicine, Section of Hematology/Oncology, Baylor College of Medicine
Mary K. McKenna: Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital, Houston Methodist Hospital
Matthew Dysthe: Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital, Houston Methodist Hospital
Youngrock Jung: Department of Medicine, Section of Hematology/Oncology, Baylor College of Medicine
Robin Parihar: Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital, Houston Methodist Hospital
Malcolm K. Brenner: Department of Medicine, Section of Hematology/Oncology, Baylor College of Medicine
Masataka Suzuki: Department of Medicine, Section of Hematology/Oncology, Baylor College of Medicine

DOI: https://doi.org/10.1038/s42003-021-01914-8
Journal volume & issue: Vol. 4, no. 1
pp. 1 – 13

Abstract

Read online

Rosewell Shaw et al. show that a previously developed immunotherapy strategy, coupling oncolytic adenoviral immunotherapy with clinically tested HER2-specific CAR T-cells, is effective against pancreatic ductal adenocarcinoma (PDAC). This combination therapy produces a curative response in both PDAC xenografts and humanized mouse models.

Published in Communications Biology

ISSN: 2399-3642 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science: Biology (General)
Website: https://www.nature.com/commsbio/

About the journal